Učitavanje...
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer...
Spremljeno u:
| Izdano u: | Immune Netw |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The Korean Association of Immunologists
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7049584/ https://ncbi.nlm.nih.gov/pubmed/32158598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4110/in.2020.20.e10 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|